Welcome to our dedicated page for SenesTech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SenesTech, Inc. filings document the public-company records of a Nasdaq-listed developer of fertility-control products for rodent and animal pest management. Recent Form 8-K reports cover operating results, commercial updates tied to e-commerce and Evolve products, and material governance events involving executive appointments, departures, employment terms, and compensation arrangements.
SenesTech proxy materials describe annual meeting matters, board and executive compensation disclosures, shareholder voting items, and governance information. The filings also identify the company’s registered common stock, par value, trading symbol SNES, and Nasdaq listing, providing formal disclosure around capital structure and corporate administration.
SenesTech (SNES) announced its third‑quarter results for the period ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1 to a Form 8‑K under Item 2.02.
The disclosure is presented as furnished, not filed, under the Exchange Act. The company also stated it has no obligation to publicly update forward‑looking statements. The text referenced in the report may be available on www.senestech.com.
SenesTech (SNES) reported an insider ownership update via Form 3 for an officer serving as Interim Chief Operating Officer. The filing indicates no securities are beneficially owned (0) by the reporting person. The event date was 10/15/2025, and the form was filed by one reporting person.
The document was executed by Thomas C. Chesterman as attorney-in-fact.
SenesTech, Inc. (SNES) appointed Michael Edell as Interim Chief Operating Officer effective October 15, 2025. The company states there are no family relationships and no arrangements or understandings related to his election.
Edell will receive $30,000 per month and is eligible for a bonus at the Board’s discretion. Given the interim status, he will not receive standard benefits such as health insurance, retirement plans, paid time off, or other fringe benefits, and he will not be entitled to severance or other post‑termination compensation. He will be reimbursed for reasonable business expenses and will enter into the company’s standard indemnification agreement for officers.
SenesTech, Inc. filed an 8-K to report that it has filed a prospectus supplement registering an additional $7,580,675 of shares of its common stock under its existing at-the-market offering agreement with H.C. Wainwright & Co., LLC dated June 20, 2024. These shares may be issued from time to time through the sales agent under that agreement. The company states that, prior to this filing, it has already sold an aggregate of $3,048,894.72 of common stock through the same at-the-market program. A legal opinion from Greenberg Traurig, LLP regarding the validity of the newly registered shares is included as Exhibit 5.1, with its consent included as Exhibit 23.1.
SenesTech, Inc. has filed a new prospectus supplement allowing it to offer and sell up to $7,580,675 of common stock from time to time through H.C. Wainwright & Co. under an at-the-market Sales Agreement. This capacity reflects the $10,629,569.80 limit under General Instruction I.B.6 of Form S-3, after deducting $3,048,894.72 of securities sold in the prior 12 months. As of this supplement, SenesTech had 5,185,333 shares of common stock outstanding and an aggregate market value of non-affiliate holdings of $31,888,709.40, and sales remain subject to the one-third cap while that market value is below $75,000,000.
SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.
The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.
SenesTech, Inc. (SNES) reporting: Lynn Yako filed an Initial Statement of Beneficial Ownership (Form 3) identifying her relationship to the issuer as a Director and reporting no securities beneficially owned. The event date listed is 07/05/2025 and the form bears a signature dated 08/02/2025. The filing includes an exhibit: a Limited Power of Attorney.
SenesTech, Inc. (a Delaware corporation with principal place in Surprise, Arizona) filed a Form D disclosing a Regulation D private offering of common stock warrants that raised an aggregate of $273,539. The filing reports the total amount sold as $273,539 with $0 remaining to be sold and indicates the offering relied on Rule 506(b). Five investors participated and the issuer states $0 of the gross proceeds were used to pay named executive officers.
The placement agent disclosed is H.C. Wainwright & Co., LLC, and the filing estimates sales commissions of $474,589. It also discloses placement agent warrants to purchase up to 72,944 shares at an exercise price of $5.4219 per share, plus accountable expenses and a management fee. The offering is not tied to a business combination and is not intended to last more than one year.
PFS Cap Mgt Co and PFS Trust report beneficial ownership of 340,000 shares of SenesTech, Inc., representing 9.99% of the outstanding common stock based on 2,247,691 shares outstanding as of June 24, 2025, per the company's Prospectus Supplement No. 2. The reported position includes 120,000 shares issuable upon exercise of warrants held by the Trust but those warrants are subject to a 9.99% exercise blocker, so the Reporting Persons cannot currently exercise all warrants to exceed the 9.99% threshold. The filing shows shared voting and dispositive power over 340,000 shares and no sole voting or dispositive power. The Schedule 13G/A is signed by John David Kessler on August 12, 2025.